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Abstract
Introduction: The protective effects of carbamylated darbepoetin on the model of ischemic optic neuropathy in rats 
were revealed.
Objectives: To increase the effectiveness of pharmacological correction of experimental ischemic optic neuropathy in 
an experiment by using carbamylated darbepoetin.
Methods: Measuring the microcirculation level in the retina of rats was carried out using laser Doppler flowmetry 
(LDF). Registration was done by the data acquisition system Biopac-systems MP-150 and AcqKnowledge 4.2 pro­
gramme.
For microscopy and morphometry, the prepared microslides were scanned using Mirax Desk, a computerised archiving 
and image analysis system. Image analysis and morphometry were carried out by Pannoramic Viewer 1.15.4.
Results and discussion: In the group with correction of ischemic optic neuropathy by carbamylated darbepoetin, 300 
pg/kg, the microcirculation level increases by 41.9%, p<0.05 in comparison with the control group, but also below 
the norm values by 20.3%, p<0.05. In the group with correction by recombinant erythropoietin, 50 IU/kg, the micro­
circulation rate increases by 36.7%, p<0.05 in comparison with the control group and significantly lower - by 23.3%, 
p<0.05 - in comparison with the group of intact animals. Qualitative and quantitative morphological indices (thickness 
of retinal layers) helped to reveal a neuroprotective effect of carbamylated darbepoetin to a greater extent than that of 
recombinant erythropoietin.
Conclusion: The obtained data allow drawing a conclusion about partial restoration of blood flow and preservation 
of neuronal retinal structures when correcting ischemic optic neuropathy in rats with carbamylated darbepoetin to a 
greater extent than with recombinant erythropoietin.
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Introduction
Ischemic optic neuropathy usually has a sudden onset, 
in some cases there is a progressive visual loss within 
2 weeks (Riordan-Eva 2004). The clinical signs of op-
tic neuropathy are acute or chronic vision loss with a 
visual field defect, dyschromatopsia and a relative affer­
ent pupillary defect (Prasad et al. 2010, Behbehani 2007, 
Hornyak et al. 2009). In order to make a correct diagno­
sis, it is necessary to examine the eye fundus (Rizzo et al.
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2002) and to undertake electrophysiological (Holder et al. 
2009), serological and genetic tests (Purvin 2000).
Non-arteritic anterior ischemic optic neuropathy is the 
most common form of ischemic optic neuropathy. Pa­
tients are usually over 50 years with vasculopathogenic 
risk factors (diabetes, arterial hypertension etc.) (Berry 
et al. 2017).
Atrophy of the inner layers of the retina is observed 
in the eyes with non-arteritic ischemic optic neurop­
athy (Rebolleda et al. 2015), but a significant part of 
the layer of nerve fibres and the layer of ganglion cells 
is preserved in patients even with no light perception 
(Miki et al. 2015).
The morphological changes include severe oedema af­
ter the onset of non-arteritic ischemic optic neuropathy, 
which rapidly turns into atrophy. Within 2 months, in more 
than 80% of patients, the thickness of the nerve fibres’ lay­
er is below the normal range (Kernstock et al. 2014).
In the treatment of retinal and optic nerve ischemia, 
they use drugs that improve retinal microcirculation and 
rheological blood properties (rheopolyglukin, pentoxi­
fylline), vasodilators (eufyllin, xanthinol nicotinate etc.) 
(Moshetova et al. 2009).
At present, there is no unique and well-proven method 
of treating non-arteritic anterior ischemic optic neuropathy, 
despite the fact that it is the main pathology that affects the 
optic nerve in elderly people (Nuzzi and Monteu 2017).
Modified erythropoietin has been created -  carbam­
ylated erythropoietin -  which has no erythropoietic effect, 
but at the same time keeps its neuroprotective properties.
Darbepoetin is a hyperglycosylated variant of recom­
binant human erythropoietin and, when compared to nat­
ural erythropoietin, darbepoetin has a three-fold longer 
half-life. For darbepoetin, it has been proved that it is as 
an equally effective neuroprotective agent as erythropoi­
etin (Kertmen et al. 2014). At the same time, in animal 
models, its effectiveness in case of strokes was the same 
when administered weekly in comparison to the daily use 
of erythropoietin (Grasso et al. 2009). Thus, its effective 
dose is less and its application is less frequent than that 
of erythropoietin.
The assumption is that carbamylated darbepoetin will 
exhibit a protective effect on the model of ischemic optic 
neuropathy. The advantage of carbamylated darbepoetin 
against darbepoetin is that there is no influence on eryth- 
ropoiesis.
In view of the above, the study relevance can be seen 
in studying the protective effects of carbamylated darbe- 
poetin along with evaluating morphometric and microcir­
culatory changes in the retina in rats when ischemic optic 
neuropathy is corrected.
Objectives
To increase the effectiveness of pharmacological correc­
tion of ischemic optic neuropathy in an experiment using 
carbamylated darbepoetin.
Methods
The experiments were made on Wistar male rats weighing 
225-275 g. For the study, the rats had no external signs of 
disease and had passed through quarantine. The ethical 
principles for handling laboratory animals were followed 
in compliance with “The European Convention for the 
Protection of Vertebral Animals Used for Experimental 
and Other Scientific Purposes. CETS No. 123”. All op­
erations and other manipulations in rats were carried out 
under general anaesthesia with intraperitoneal (i/p) ad­
ministration of an aqueous solution of chloral hydrate in 
a dose 300 mg/kg of rat mass.
The following experimental groups were included in 
the study: the first group (n = 10) -  a group of intact ani­
mals, the second group (n = 10) -  a group with simulating 
ischemic optic neuropathy (control), the third group (n = 
10) -  included animals with correction of ischemic optic 
neuropathy by carbamylated darbepoetin (Carbamylated 
darbepoetin, injectable solution, Pharmapark Ltd, Rus­
sia); the fourth group (n = 10) -  included animals with the 
correction of pathology by recombinant erythropoietin 
(“Epokrin” epoetin alfa, Federal State Unitary Enterprise 
“State Research Institute of Highly Pure preparations”, 
Russia) (reference drug).
Based on the literature data, recombinant erythropoietin 
in a dose 50 IU/kg of rat mass has no effect on erythropoie- 
sis, but has a retinoprotective effect (Shabelnikova 2016).
Simulation of the ischemic optic neuropathy was per­
formed by daily i/p injection of a non-selective inhibi­
tor of NO-synthases N-nitro-L-arginine methyl ester 
(L-NAME) (Sigma, Germany) in rats in a dose of 12.5 
mg/kg in the form of an aqueous solution for 28 days 
and a single increase in intraocular pressure (IOP) to 110 
mmHg by applying mechanical pressure to the anterior 
chamber of the eye (Shabelnikova 2016) for 5 minutes on 
the 26th day of the experiment.
Carbamylated darbepoetin was injected subcutaneous­
ly (s/c) in a dose of 300 pg/kg of rat mass to the withers 
area once every 3 days (1st, 4th, 7th, 10th, 13th, 16th, 19th, 
22nd, 25th and 28th days of the experiment), 30 minutes 
before administering L-NAME.
In the fourth group of animals, recombinant erythro­
poietin was injected into the withers area in a dose of 50 
IU/kg of rat mass (Peresypkina et al. 2014) once every 3 
days, 30 minutes before administering L-NAME.
To measure blood pressure in rats (in the tail) on the 
29th day of the experiment, a non-invasive blood pressure 
measurement system was used in small animals NIBP200 
within the data acquisition system Biopac-systems MP- 
150 (USA).
The measurement of the microcirculation level in the 
rats’ retina was done by using the LDF method on the 29th 
day of the experiment under general anaesthesia. Reg­
istration was done with the help of the data acquisition 
system Biopac-systems MP-150 and the TSD-144 needle 
probe (USA) using the AcqKnowledge 4.2 programme. 
After anaesthetising the animal, the microcirculation lev­
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el was assessed at ten points around the eyeball with the 
duration of recording the microcirculation level readings 
at one point being 20 seconds. Based on the results of the 
microcirculation level at each point, the mean was calcu­
lated, which was considered as an indicator of the retinal 
microcirculation level in a given experimental animal. 
The microcirculation value in the animals’ group was cal­
culated as the mean of the values obtained for each ex­
perimental animal in the group (Peresypkina et al. 2016).
After measuring the blood flow in the retina, the eyes 
were completely removed along with the adjacent struc­
tures on the 29th day of the experiment for morphometric 
examination and were fixed by immersion in 10% forma­
lin solution. After fixing, the eyes were sectioned into two 
parts through the centre and both halves were processed 
into paraffin by routine methods. Also in the meridian di­
rection, serial sections were made with a thickness of 5-7 
pm, which were stained with haematoxylin and eosin. 
The stages of histological processing were performed us­
ing Leica equipment (Germany). For microscopy, mor­
phometry and archiving, the prepared microslides were 
scanned using Mirax Desk, a computerised archiving and 
image analysis system. Image analysis and morphome­
try were carried out by a Pannoramic Viewer 1.15.4. The 
thickness of the layers of the retina was measured in a 
strictly perpendicular direction to within one hundredth 
of a micrometre. In each animal, five representative ar­
eas, free from artifacts of treated material, were meas­
ured. The quantitative data were recorded in MS Excel 
spreadsheets.
For all the data, descriptive statistics were applied and 
the data were checked for the distribution normality. The 
type of distribution was determined by the Shapiro-Wilk 
criterion. At a normal distribution, the mean value (M) 
and the standard error of the mean (m) were calculated. 
At an abnormal distribution, the median (Me) and the 
quartile range (QR) were calculated. The intergroup dif­
ferences were analysed by parametric (Student’s t-test) or 
non-parametric (Mann-Whitney test) methods, depend­
ing on the distribution type. The differences were deter­
mined at a 0.05 significance level. The statistical analysis 
was performed using the software Statistica 10.0.
Results and discussion
The authors used on Wistar rats a model of ischemic optic 
neuropathy, pathogenesis of which, in particular, is as­
sociated with the development of arterial hypertension 
affected by daily i/p administration of L-NAME in a dose 
12.5 mg/kg/day for 28 days (Belous et al. 2015) (SBP 
139.2 ± 5.4 mmHg, DBP 104.2 ± 4.7 mmHg in the group 
of intact animals; SBP 204.8 ± 10.0 * mmHg, DBP 164.2 
± 5.9 * mmHg in the group with pathology simulation, * 
- p<0.05 in comparison with the group of intact animals).
To confirm the formation of the ischemic optic neurop­
athy in rats on the 29th day of the experiment, the results of 
LDF in the retina and of morphometric studies were used.
The results of measuring the microcirculation level in 
the retina in the experimental animals are shown in Table 1.
Table 1. Results of LDF in the Retina in Experimental Animals on 29th Day of the Experiment (M ± m; n = 10).
Experimental groups Microcirculation level, PU
Intact 743.0 ± 20.9
Control 417.2 ± 13.1*
Correction by carbamylated darbepoetin, 300 pg/kg 592.4 ± 9.6*у
Correction by recombinant erythropoietin, 50 IU/kg 570.5 ± 10.5*у
Note: * -  p<0.05 compared with the group of intact animals, у - р<0.05 compared with the control group, PU - perfusion units.
In the group with simulated ischemic optic neurop­
athy, the microcirculation level significantly decreases 
by 43.9 %, p<0.05 in comparison with the group of in­
tact animals. In the group with the correction of pathol­
ogy by carbamylated darbepoetin, this indicator signif­
icantly increases by 41.9%, p<0.05 in comparison with 
the group without correction, but it is also 20.3% lower 
than the norm values, p<0.05. In the group with correc­
tion by recombinant erythropoietin, the microcircula­
tion level in the retina significantly increases by 36.7%, 
p<0.05 in comparison with the group without correction 
and is significantly lower - by 23.3%, p<0.05 -  in com­
parison with the group of intact animals. By the degree 
of microcirculation correction in the retina, the drugs 
under study do not differ significantly from one another, 
3.9%, p=0.09.
The data obtained from measuring the microcircula­
tion level allow one to speak of a partial restoration of 
blood flow in the retina when correcting the experimental 
ischemic optic neuropathy with the test drugs.
In the group of animals with simulating experimental 
pathology, all rats showed pronounced morphological 
changes in the neuronal structures of the retina affect­
ed by circulatory disturbances. In the layer of rods and 
cones, represented by the dendrites of photoreceptor neu­
rons, discomplexation of the structure was revealed. The 
layer lost its normal radial striation, created due to the 
compact arrangement of neuronal processes and obtained 
a spongiform loose shape (Figs. 1 and 2).
Signs of dendrites’ destruction through lumpy decom­
position are common in the form of their transformation 
into oxyphilic chaotically located globular structures.
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Figure 1. Retinal changes in experimental ischemic optic neu­
ropathy: (A) discomplexation of dendrites in the photoreceptor 
layer and perikaryons in the outer nuclear layer to form inter­
cellular clefts of oedematous type (B) discomplexation of struc­
tures and oedematous loose shape of inner nuclear (INL) and 
inner retinal (IRL) layers, pronouncedly full-blooded small vein 
on the border of the inner retinal and ganglionic layers. Stained 
with haematoxylin and eosin. x200.
Similar changes in the outer and inner nuclear layers were 
observed in the form of decompaction of the nucleus ar­
rangement and formation of spongiform clefts, probably 
due to both intercellular oedema and the lytic changes in 
the perikaryons of photoreceptor neurons (Fig. 2).
The retinal layers were subjected to spongiform trans­
formation. Within the area of the optic nerve disc, an 
obvious thinning of the retinal layers is microscopically 
revealed. The most severe changes were observed at the 
edges of the optic nerve disc (Fig. 3) and in the ganglionic 
layer of both the posterior and anterior parts of the retina.
The edges of the optic disc are sharply oedematous, with 
pronounced cell devastation. In the ganglionic layer, there 
is a full-blown peri- and intracellular oedema and a part of 
neurons with lytic changes in pericarions. All these chan­
ges are accompanied by severe circulatory disturbances, 
mainly in the small veins and venous part of the microcir­
culatory bed in the form of extensive plethora, erythrosta-
Figure 2. Retinal changes in experimental ischemic optic neu­
ropathy: marked discomplexation of the structure of the photore­
ceptor (PR) and outer nuclear (ONL) layers; in the photoreceptor 
layer changes of dendrites of rods and cones through lumpy de­
composition. Stained with haematoxylin and eosin. x400.
sis and sludges in venules (Figs. 1 and 3); in the centres 
of pronounced venous plethora, the inner glial boundary 
membrane is often destroyed and intraocular haemorrha­
ges in the posterior chamber are detected (Fig. 4).
In the group of animals with administered carbamyla­
ted darbepoetin, significant differences in the retinal struc­
ture were revealed in comparison with those developing 
in experimental pathology. The overall structure of the 
neuronal layers of the retina is almost unchanged. The dis­
complexation of structures and oedematous changes, simi­
lar to those in ischemic optic neuropathy, are moderately 
expressed. The main changes are observed in the photore­
ceptor and ganglionic layer (Fig. 5). The optic nerve disc 
and the nerve itself have no signs of damage. At the same 
time, circulatory disorders in both the retina and extraocu­
lar vessels remain mainly in the form of venous plethora 
and stasis in the vessels of the microcirculatory bed.
In the group with the recombinant erythropoietin cor­
rection, the structure of the retinal layers is unchanged; 
there are observed hypertensive changes of the orbital 
artery, uneven contours of the intima with deformation 
of the endothelium. Despite significant circulatory disor­
ders in the microcirculatory vessels of the retina, as well
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Figure 3. Details of changes in the optic nerve disc in exper­
imental ischemic optic neuropathy: (A) discomplexation of 
structures in the inner retinal layer (bottom part of the micro­
photo), pronounced pericellular oedema, lytic changes of indi­
vidual neurons, plethora and erythrostasis in the venule (arrow) 
in the ganglionic layer. (B) pronounced oedema at the edge of 
the disc. Stained with haematoxylin and eosin. x200.
as extraocular vessels (Fig. 6), neuronal structures were 
relatively intact.
The most sensitive to the damaging effect in the used 
pathology model are the retinal layers formed by neu­
ronal processes and synaptic contacts (photoreceptor and 
retinal layers). However, the preservation of the neuron 
body structures -  their nuclei and perikaryons -  can be 
evidence of their potential viability and capacity for re­
storing both neuronal processes, including the sensory
Figure 4. Changes in the retina in experimental ischemic optic 
neuropathy: a focus of pronounced venous plethora (bottom part 
of the microphoto) of the retina and intraocular haemorrhage; 
above the arrow is a fragment of a detached internal border glial 
membrane. Stained with haematoxylin and eosin. x200.
outer segments of rods and cones that make up the photo­
receptor layer and the inter-neuronal connections.
The results of morphometry of retinal layers quantita­
tively confirm the described qualitative changes and to­
gether testify to the development of cellular destruction 
and atrophy of retinal layers in simulating ischemic optic 
neuropathy (Table 2).
A significant decrease was revealed in the thickness of 
the photoreceptor layer, which indicates damage to the 
perikaryons of photosensitive cells as well as to both seg­
ments (external and internal) of their dendrites in the con­
trol group. An increase in the thickness of the inner nucle­
ar layer is mostly associated with oedematous changes. 
This can also explain an increase in the thickness of the 
inner retinal as well as ganglionic layers, although the 
spongiform changes in the retinal layer, similar to those 
in the white matter of the brain and spinal cord in case 
of blood circulation disorders, can reflect the destruction 
of both the neuronal processes and the synaptic contacts 
formed by them.
The neuroprotective effect of carbamylated darbepoe- 
tin is proved by morphometric indices of the thickness of 
the retinal layers (Table 2). In the ganglionic layer, even
Table 2. Thickness of Retinal Layers in Experimental Groups (M ± m).
Experimental groups
Retinal layers Intact Control CD RE
Photoreceptor layer 52.6 ± 1.7 13.9 ± 0.6* 52.6 ± 1.3 42.4 ± 1.5*у
Inner nuclear 26.4 ± 1.3 39.9 ± 0.6* 34.4 ± 0.6* 30.7 ± 1.5*у
Inner retinal 45.4 ± 2.6 53.7 ± 1.6* 46.0 ± 1.0у 53.4 ± 2.1*
Ganglionic and nerve fibres 17.8 ± 1.0 22.3 ± 0.8* 18.2 ± 0.7У 17.8 ± 1.0У
Note: * -  p<0.05 compared with the group of intact animals, у -  р<0.05 compared with the control group. CD -  group with correc­
tion by carbamylated darbepoetin, 300 pg/kg, RE -  group with recombinant erythropoietin correction, 50 IU/kg.
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Figure 5. Details of retinal changes in the group with correction 
by carbamylated darbepoetin: spongiosis of the inner retinal 
layer (bottom parts of the microphotos), perineuronal oedema 
in the ganglionic layer (top parts). Stained with haematoxylin 
and eosin. x400.
with pronounced perineuronal oedema and chromatoly­
sis, the general structure of the neurons and their nuclei 
were preserved, which may evidence their viability.
By the quantitative parameters of the retinal layer 
thickness, the neuroprotective effect is somewhat less 
expressed in recombinant erythropoietin than in carbam- 
ylated darbepoetin.
Thus, by qualitative and quantitative morphological 
indices, the neuroprotective effect of carbamylated darb­
epoetin in a dose of 300 gg/kg was revealed on the model 
of ischemic optic neuropathy in Wistar rats. Administra­
tion of the drug did not affect the morphological changes 
in the blood vessels, but the neuronal structures of the ret­
ina remained more intact than in the pathology simulat­
ing group. A similar pattern was found in the group with 
administration of recombinant erythropoietin in a dose of 
50 IU/kg. Despite significant circulatory disturbances in 
the microcirculatory vessels of the retina, as well as in 
extraocular vessels, the neurons were relatively intact.
Figure 6. Details of retinal changes in the group with correc­
tion by recombinant erythropoietin: (A) posterior pole of the 
eye with optic nerve (ON) and posterior retina. The structure of 
the retinal layers is unchanged; the intraorbital artery is shown 
by arrow. (B) hypertensive changes in the orbital artery (details 
from Fig. A): uneven intima contours with deformation of the 
endothelium in the form of “palisade”, dystrophic changes in 
smooth medial myocytes, destruction of the internal elastic 
membrane. Stained with haematoxylin and eosin. x200.
The main factors in the development of retinal angiop­
athy are disorders of general haemodynamics and local 
changes in the vessel walls. Amongst the local changes, 
the most important are damage to the vascular endotheli­
um (Tinjust et al. 2002).
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In this connection, it is necessary to find new methods 
of retinoprotection to possibly reduce the negative con­
sequences of ischemia of the retina and the optic nerve. 
The segment of medicines to treat neurovascular diseases 
of the retina as a complication of arterial hypertension is 
to be expanded due to an increase in the disease rate and 
lack of remedies for specific correction of ischemic dam­
age to the retinal vasculature.
Conclusion
In the group with correcting ischemic optic neuropathy 
by carbamylated darbepoetin in a dose of 300 pg/kg with 
subcutaneous administration every 3 days (1st, 4th, 7th, 
10th, 13th, 16th, 19th, 22nd, 25th, 28th days of the experiment), 
the microcirculation level is significantly increased by 
41.9%, p<0.05 compared with the control group, but is 
also 20.3% lower than the normal values, p<0.05. In the 
group with the correction by recombinant erythropoietin 
in a dose of 50 IU/kg, the microcirculation level in the
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